Can we develop biomarkers that predict response of cancer patients to immunotherapy?

References

• Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Current Opinions in Cell Biology 1999; 11: 255–260
   PubMed Web of Science ®Google Scholar
• Baeuerle PA, Baltimore D. NF-kappa B: ten years after. Cell 1996; 87: 13–20
   PubMed Web of Science ®Google Scholar
• Deveraux QL, Roy N, Stennicke HR, Van Arsdale T, Zhou Q, Srinivasula SM, Alnemri ES, Salvesen GS, Reed JC. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO Journal 1998; 17: 2215–2223
   PubMed Web of Science ®Google Scholar
• Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000; 102: 33–42
   PubMed Web of Science ®Google Scholar
• Garban HJ, Bonavida B. Nitric oxide inhibits the transcription repressor Yin-Yang 1 binding activity at the silencer region of the Fas promoter: a pivotal role for nitric oxide in the up-regulation of Fas gene expression in human tumor cells. Journal of Immunology 2001; 167: 75–81
   PubMed Web of Science ®Google Scholar
• Huerta-Yepez S, Vega M, Jazirehi A, Garban H, Hongo F, Cheng G, Bonavida B. Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression. Oncogene 2004; 23: 4993–5003
   PubMed Web of Science ®Google Scholar
• Jazirehi AR, Vega MI, Chatterjee D, Goodglick L, Bonavida B. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab. Cancer Research 2004; 64: 7117–7126
   PubMed Web of Science ®Google Scholar
• Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S, Hengartner H, Golstein P. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994; 265: 528–350
   PubMed Web of Science ®Google Scholar
• Mizutani Y, Hongo F, Sato N, Ogawa O, Yoshida O, Miki T. Significance of serum soluble Fas ligand in patients with bladder carcinoma. Cancer 2001; 92: 287–293
   Google Scholar
• Mizutani, Y, Nakaishi, H, Yamamoto, K, Nan Li, Y, Matsubara, H, Mikami, K, Okihara, K, Kawauchi, A, Bonavida, B, Miki, T. 2005. Downregulation of Smac/DIABLO expression in renal cell carcinoma and its prognostic significance. Journal of Clinical Oncology, 28:448–454.
   Google Scholar
• Mizutani Y, Yoshida O, Bonavida B. Prognostic significance of soluble Fas in the serum of patients with bladder cancer. Journal of Urology 1998; 160: 571–576
   Google Scholar
• Mizutani Y, Yoshida O, Ukimura O, Kawauchi A, Bonavida B, Miki T. Prognostic significance of a combination of soluble Fas and soluble Fas ligand in the serum of patients with Ta bladder cancer. Cancer Biotherapy & Radiopharmaceutics 2002; 17: 563–567
   PubMedGoogle Scholar
• Nagata S. Apoptosis by death factor. Cell 1997; 88: 355–365
   PubMed Web of Science ®Google Scholar
• Ng CP, Bonavida B. A new challenge for successful immunotherapy by tumors that are resistant to apoptosis: two complementary signals to overcome cross-resistance. Advanced Cancer Research 2002a; 85: 145–174
   PubMed Web of Science ®Google Scholar
• Ng CP, Bonavida B. X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO). Molecular Cancer Therapy 2002b; 1: 1051–1058
   PubMed Web of Science ®Google Scholar
• Patel NH, Rothenberg ML. Multidrug resistance in cancer chemotherapy. Investigative New Drugs 1994; 12: 1–13
   PubMed Web of Science ®Google Scholar
• Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 2004; 23: 2934–2949
   PubMed Web of Science ®Google Scholar
• Ravi R, Bedi GC, Engstrom LW, Zeng Q, Mookerjee B, Gelinas C, Fuchs EJ, Bedi A. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB. National Cell Biology 2001; 3: 409–416
   PubMed Web of Science ®Google Scholar
• Seligson, D, Horvath, S, Huerta-Yepez, S, Hanna, S, Garban, H, Roberts, A, Shi, T, Liu, X, Chia, D, Goodglick, L, Bonavida, B. 2005. Expression of transcription factor Ying-Yang 1 in prostate cancer. International Journal of Oncology. 27:131–141.
   Google Scholar
• Sogn JA. Tumor immunology: the glass is half full. Immunity 1998; 9: 757–763
   PubMed Web of Science ®Google Scholar
• Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. Journal of Experimental Medicine 1997; 186: 2045–2050
   PubMed Web of Science ®Google Scholar
• Tan B, Piwnica-Worms D, Ratner L. Multidrug resistance transporters and modulation. Current Opinions in Oncology 2000; 12: 450–458
   PubMed Web of Science ®Google Scholar
• Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Natural Medicine 1998; 4: 31–36
   PubMed Web of Science ®Google Scholar
• Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, Motoyoshi K, Mizuki M, Tagawa S, Ohga S, Hatake K, Drummond AH, Nagata S. Fas ligand in human serum. Natural Medicine 1996; 2: 317–322
   PubMed Web of Science ®Google Scholar
• Tanaka M, Suda T, Takahashi T, Nagata S. Expression of the functional soluble form of human fas ligand in activated lymphocytes. EMBO Journal 1995; 14: 1129–1135
   PubMed Web of Science ®Google Scholar
• Vega MI, Huerta-Yepaz S, Garban H, Jazirehi A, Emmanouilides C, Bonavida B. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene 2004; 23: 3530–3540
   PubMed Web of Science ®Google Scholar
• Wang CY, Mayo MW, Baldwin AS, Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 1996; 274: 784–787
   PubMed Web of Science ®Google Scholar
• Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS, Jr. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998; 281: 1680–1683
   PubMed Web of Science ®Google Scholar